Context Therapeutics Inc [CNTX] stock prices are down -3.18% to $0.97 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTX shares have gain 15.95% over the last week, with a monthly amount glided 7.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Context Therapeutics Inc [NASDAQ: CNTX] stock has seen the most recent analyst activity on September 18, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $5. On January 08, 2025, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $4 on the stock. D. Boral Capital started tracking the stock assigning a Buy rating and suggested a price target of $9 on November 25, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $4.50 as its price target on May 16, 2024.
The stock price of Context Therapeutics Inc [CNTX] has been fluctuating between $0.49 and $2.59 over the past year. Currently, Wall Street analysts expect the stock to reach $5.25 within the next 12 months. Context Therapeutics Inc [NASDAQ: CNTX] shares were valued at $0.97 at the most recent close of the market. An investor can expect a potential return of 441.24% based on the average CNTX price forecast.
Analyzing the CNTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.39 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Context Therapeutics Inc [NASDAQ:CNTX]’s Current Ratio is 19.04. In addition, the Quick Ratio stands at 19.04 and the Cash Ratio stands at 18.33.
Transactions by insiders
Recent insider trading involved Lehr Martin A., Chief Executive Officer, that happened on Jun 09 ’25 when 100000.0 shares were purchased. Chief Legal Officer, Corp. Sec, Levit Alex C. completed a deal on Jun 06 ’25 to buy 20000.0 shares. Meanwhile, Chief Financial Officer Minai-Azary Jennifer Lynn bought 40010.0 shares on Jun 06 ’25.
